ZS Pharma Announces Start of Enrollment of Phase 3 Long-Term Maintenance Study of ZS-9 in Patients with Hyperkalemia

–Open-Label Safety Study Evaluating Long-Term Safety and Efficacy of Oral Investigational Hyperkalemia Treatment—

Coppell, Texas – June 26, 2014 – ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that it has begun enrolling patients in ZS005, a Phase 3 open-label, 12-month, long-term maintenance study of ZS-9, an investigational treatment for hyperkalemia.

Read More

ZS Pharma Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Over-Allotment Option

Coppell, Texas – June 23, 2014 – ZS Pharma, Inc., a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced the closing of its initial public offering of 6,836,111 shares of common stock at a public offering price of $18.00 per share.

Read More

ZS Pharma, Inc. Announces Pricing of Initial Public Offering

COPPELL, Texas–(BUSINESS WIRE)– ZS Pharma, Inc., a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced the pricing of its initial public offering of 5,944,444 shares of its common stock at a price to the public of $18.00 per share.

Read More

ZS Pharma to Present Data from Phase 3 Trial of ZS-9 in Late-Breaking Poster Presentation at the American Diabetes Association (ADA) Scientific Sessions

Coppell, Texas – June 13, 2014 – ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that data from a pivotal Phase 3 trial of ZS-9, its investigational treatment for hyperkalemia, will be presented as a late-breaking clinical trial poster during the 74th American Diabetes Association (ADA) Scientific Sessions being held in San Francisco from June 13 to 17, 2014.

Read More